{"id":"NCT00219544","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.","officialTitle":"A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2005-09-22","resultsPosted":"2009-06-02","lastUpdate":"2021-01-22"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neuropathic Pain"],"interventions":[{"type":"DRUG","name":"Pregabalin (Lyrica)","otherNames":[]},{"type":"DRUG","name":"Pregabalin (Lyrica)","otherNames":[]},{"type":"DRUG","name":"Pregabalin (Lyrica)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"PLACEBO_COMPARATOR"}],"summary":"This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).","primaryOutcome":{"measure":"Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase","timeFrame":"9 weeks","effectByArm":[{"arm":"Pregabalin","deltaMin":2.84,"sd":0.18},{"arm":"Placebo","deltaMin":3.62,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0018"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":30,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Dizziness","Somnolence","Dry mouth","Peripheral edema","Headache"]}}